Melbourne, Sep 30, 2010 (ABN Newswire) - Benitec Limited (ASX:BLT) (PINK:BNIKF) are delighted to announce that the United States Patent and Trademark Office's (USPTO) Board of Patent Appeals and Interferences has issued a decision reversing all previous rejections in the US 6,573,099 (the '099 Graham patent) appeal.
Benitec's Chief Executive Officer, Dr Peter French, said "This decision is the best possible outcome for Benitec and CSIRO. All of the rejections were reversed, confirming Benitec and CSIRO's long held belief in this patent and our RNA interference technology."
The Company will make a further announcement to the market once the full implications of this decision have been reviewed.
Benitec Limited (ASX:BLT) (PINK:BNIKF) holds a dominant position in expressed RNA interference (RNAi)-based human therapeutics, with a transformational platform technology supported by a robust and extensive intellectual property portfolio. Benitec is leveraging this platform to develop and build a pipeline of expressed RNAi therapeutics focusing on treatment and alleviation of cancer and infectious disease. With strong global partnerships and committed scientific and clinical investigators, Benitec Ltd aims to deliver a range of novel RNAi-based therapeutics to the clinic in partnership with the pharmaceutical industry.
Contact
Peter French Chief Executive Officer Benitec Limited Mob: +61-412-457-595 Email: pfrench@benitec.com http://www.benitec.com
ASX:BLT) (
Benitec Limited
){kind=link}